11 research outputs found
Effect of health information technology interventions on lipid management in clinical practice: A systematic review of randomized controlled trials
BACKGROUND: Large gaps in lipid treatment and medication adherence persist in high-risk outpatients in the United States. Health information technology (HIT) is being applied to close quality gaps in chronic illness care, but its utility for lipid management has not been widely studied. OBJECTIVE: To perform a qualitative review of the impact of HIT interventions on lipid management processes of care (screening or testing; drug initiation, titration or adherence; or referrals) or clinical outcomes (percent at low density lipoprotein cholesterol goal; absolute lipid levels; absolute risk scores; or cardiac hospitalizations) in outpatients with coronary heart disease or at increased risk. METHODS: PubMed and Google Scholar databases were searched using Medical Subject Headings related to clinical informatics and cholesterol or lipid management. English language articles that described a randomized controlled design, tested at least one HIT tool in high risk outpatients, and reported at least 1 lipid management process measure or clinical outcome, were included. RESULTS: Thirty-four studies that enrolled 87,874 persons were identified. Study ratings, outcomes, and magnitude of effects varied widely. Twenty-three trials reported a significant positive effect from a HIT tool on lipid management, but only 14 showed evidence that HIT interventions improve clinical outcomes. There was mixed evidence that provider-level computerized decision support improves outcomes. There was more evidence in support of patient-level tools that provide connectivity to the healthcare system, as well as system-level interventions that involve database monitoring and outreach by centralized care teams. CONCLUSION: Randomized controlled trials show wide variability in the effects of HIT on lipid management outcomes. Evidence suggests that multilevel HIT approaches that target not only providers but include patients and systems approaches will be needed to improve lipid treatment, adherence and quality
Sex Differences in the Brain: A Whole Body Perspective
Most writing on sexual differentiation of the mammalian brain (including our own) considers just two organs: the gonads and the brain. This perspective, which leaves out all other body parts, misleads us in several ways. First, there is accumulating evidence that all organs are sexually differentiated, and that sex differences in peripheral organs affect the brain. We demonstrate this by reviewing examples involving sex differences in muscles, adipose tissue, the liver, immune system, gut, kidneys, bladder, and placenta that affect the nervous system and behavior. The second consequence of ignoring other organs when considering neural sex differences is that we are likely to miss the fact that some brain sex differences develop to compensate for differences in the internal environment (i.e., because male and female brains operate in different bodies, sex differences are required to make output/function more similar in the two sexes). We also consider evidence that sex differences in sensory systems cause male and female brains to perceive different information about the world; the two sexes are also perceived by the world differently and therefore exposed to differences in experience via treatment by others. Although the topic of sex differences in the brain is often seen as much more emotionally charged than studies of sex differences in other organs, the dichotomy is largely false. By putting the brain firmly back in the body, sex differences in the brain are predictable and can be more completely understood
Healthcare Quality Improvement and Education in Diabetes Management: Overcoming Clinical Inertia to Achieve Glycemic Goals
Part one of a three-part meeting series, sponsored by the American Diabetes Association through an unrestricted education grant from sanofi-aventis US. This meeting series is intended for practicing clinicians who manage patients with diabetes.
Presentations:
Wender: 0-4:19
Rhinehart: 4:20-38:29
Ziring: 38:30-54:40
Panel discussion: 55:00-1:16:12
Foster: 1:16:13-1:22:50
Furman: 1:22:54-1:32
Total time: 1 hour and 32 minutes (audio only-no slides
Recommended from our members
Doping liquid argon with xenon in ProtoDUNE Single-Phase: effects on scintillation light
Abstract
Doping of liquid argon TPCs (LArTPCs) with a small
concentration of xenon is a technique for light-shifting and
facilitates the detection of the liquid argon scintillation
light. In this paper, we present the results of the first doping
test ever performed in a kiloton-scale LArTPC. From February to May
2020, we carried out this special run in the single-phase DUNE Far
Detector prototype (ProtoDUNE-SP) at CERN, featuring 720 t of total
liquid argon mass with 410 t of fiducial mass. A 5.4 ppm nitrogen
contamination was present during the xenon doping campaign. The goal
of the run was to measure the light and charge response of the
detector to the addition of xenon, up to a concentration of
18.8 ppm. The main purpose was to test the possibility for
reduction of non-uniformities in light collection, caused by
deployment of photon detectors only within the anode planes. Light
collection was analysed as a function of the xenon concentration, by
using the pre-existing photon detection system (PDS) of ProtoDUNE-SP
and an additional smaller set-up installed specifically for this
run. In this paper we first summarize our current understanding of
the argon-xenon energy transfer process and the impact of the
presence of nitrogen in argon with and without xenon dopant. We then
describe the key elements of ProtoDUNE-SP and the injection method
deployed. Two dedicated photon detectors were able to collect the
light produced by xenon and the total light. The ratio of these
components was measured to be about 0.65 as 18.8 ppm of xenon were
injected. We performed studies of the collection efficiency as a
function of the distance between tracks and light detectors,
demonstrating enhanced uniformity of response for the anode-mounted
PDS. We also show that xenon doping can substantially recover light
losses due to contamination of the liquid argon by nitrogen.</jats:p